Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum Phosphorus. (7th August 2019)

• Record Type: Journal Article
• Authors: Miyaoka, Daichi; Inaba, Masaaki; Imanishi, Yasuo; Hayashi, Noriyuki; Ohara, Masaya; Nagata, Yuki; Kurajoh, Masafumi; Yamada, Shinsuke; Mori, Katsuhito; Emoto, Masanori
• Is Part Of: Journal of bone and mineral research. Volume 34:Number 11(2019)
• Page Start: 2028
• Page End: 2035
• Publication Date: 2019-08-07
• Subjects: OSTEOPOROSIS -- DISORDERS OF CALCIUM/PHOSPHATE METABOLISM -- ANTIRESORPTIVES; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.3821
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Higher serum phosphorus (Pi) increases the risk for chronic kidney disease (CKD). It was reported that a single administration of denosumab or zoledronate significantly suppressed serum Pi levels as well as those of bone resorption markers in serum. Also, previous evidences suggest a link between bone anti‐resorptive therapy and vasoprotective/renoprotective effects through mechanisms that remain unexplored. The aim of this study is to assess the renoprotective effect of denosumab and involvement of denosumab‐induced reduction in serum Pi in osteoporotic patients. Osteoporotic patients ( n = 73) without overt proteinuria in dipstick test results were treated with denosumab (60 mg) every 6 months during the study period (24 months). Estimated glomerular filtration rate based on serum cystatin C (eGFRcys) was used as a filtration marker and tartrate‐resistant acid phosphatase‐5b (TRACP‐5b) as a bone resorption marker. For analysis of non‐CKD patients ( n = 56), those with eGFRcys <60 mL/min/1.73 m 2 were excluded. A single injection of denosumab suppressed serum Pi as well as TRACP‐5b during the first 6 months, whereas age‐related decline in eGFRcys was significantly reversed, with an increase of 2.75 ± 1.2 mL/min/1.73 m 2 after 24 months noted. Multivariate analysis showed that serum Pi reduction following the initial denosumab injection was positively associated with serum TRACP‐5b suppression during that same period (β = 0.241, p = 0.049). In addition, a positive association of serum Pi suppression, but not of corrected calcium or TRACP‐5b, with eGFRcys increase after 24 months (β = 0.321, p = 0.014) was found after adjustments for gender, age, BMI, antihypertensive drug use, albumin, and eGFRcys. The same was observed in osteoporotic cases restricted to non‐CKD patients. In conclusion, serum Pi reduction resulting from phosphorus load decrement from bone induced by denosumab is a determinant for eGFRcys increase. Early introduction of bone antiresorptive therapy can retain glomerular filtration in osteoporosis cases, including non‐CKD patients. © 2019 American Society for Bone and Mineral Research.